Psychedelics
Cognetivity Neurosciences Closes Final Tranche of Unit Offering
VANCOUVER, BC, Feb. 24, 2022 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB), a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments, is pleased to announce that, further to its news releases dated December 15, 2021, January 28, 2022 and February 11, 2022, it has closed the third […]
Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company”), a leading global psychedelics company, today announces several corporate updates. On February 4, 2022, the Company completed its first Jamaican psilocybin retreat of 2022 entitled “Renew Your Purpose” (see press release of December […]
Optimi Health Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements
B.C. company brings highest quality fruiting body mushroom formulations to the Canadian nutraceutical market VANCOUVER, BC (February 22, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce […]
Biomind Labs Announces Upgrade to the OTCQB® Venture Market in the United States
TORONTO, February 17, 2022–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company“) (NEO: BMND) (OTC: CRSWF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for the treatment of mental health disorders and beyond, is pleased to announce its successful upgrade from the OTC Pink to the […]
TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that, under its Co-operative Psychedelics Evaluation Platform (“COPE”) program with […]
Neuroplasticity, Psychedelics, and Mental Health
The brain is a tangled, incredibly complex mass of about 86 billion neurons. The ability to create new neurons, called neurogenesis, was long thought to stop by the age of 25. There is some debate, however, as one recent study put the age at 13, while another posited the brain continues neurogenesis into old age. […]
Psilocybin therapy is being investigated by Zollaris for the treatment of mental health and other unmet medical needs HAWKESBURY PROVIDENCE, Ontario, Feb. 16, 2022 /PRNewswire-PRWeb/ — Zollaris Laboratories Corporation. (hereafter, “Zollaris”) receives authorization from the Health Canada, Office of Controlled Substances for analytical investigation of several psilocybin powders currently permitted under license and available in Canada. The Health Canada license […]
Lobe Sciences Ltd. Strengths Its Balance Sheet
Vancouver, British Columbia–(Newsfile Corp. – February 16, 2022) – Lobe Sciences Ltd. (the “Acquiror“) announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 15, 2022, it sold 5,800,000 common shares in the capital of Ionic Brands Corp. (the “Issuer” and the common shares of the Issuer referred to as the […]
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
VANCOUVER, BC (GLOBE NEWSWIRE – February 16, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the Company’s wholly-owned subsidiary Optimi Labs […]
Enveric Biosciences Announces Pricing of $10 Million Public Offering
NAPLES, Fla., Feb. 11, 2022 /PRNewswire/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience company developing next-generation, psychedelic-inspired mental health and oncology treatments, today announced the pricing of its previously announced underwritten public offering of 20,000,000 shares of its common stock and warrants to purchase up to 20,000,000 shares of its common stock. Each […]
Improving on Psychedelics for Therapy: Interview with Mindset Pharma
Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) is a drug discovery and development company focused on second generation psychedelics derived from or inspired by their natural forebears. Mindset’s molecules are intended to improve on the original substances in various ways, from increasing safety and reducing side effects to shortening the duration and even increasing potency. […]
Virtual concert features Big Boi, Goodie Mob, Ying Yang Twins, Little Scrappy, Young Dro and more Montego Bay, Jamaica–(Newsfile Corp. – February 10, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company”), a leading global psychedelics company, today announced Marley One’s sponsorship of ‘For The Love of […]
Irwin Naturals Begins Rollup of Psychedelic Mental Health Clinics
LOS ANGELES, Feb. 09, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has taken the first step in the execution of its ketamine clinic rollup strategy – a move the Company says is motivated by an intention to become the world’s largest chain […]
Psychedelic Therapy Without the Hallucinations: Interview with BetterLife Pharma
BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FRA: NPAU) is preparing a drug candidate for the treatment of major depressive disorder (MDD) and cluster headaches. The patent-pending compound is modeled after a derivative of LSD, acting on the same receptors as LSD does but without the hallucinogenic side effects. While psychedelics have been showing great […]
Clearmind Medicine Secures CAD$1.6 Million in Private Placement
Clearmind and Medigus, the investor, intend to form a joint venture in the field of food industry, based on Clearmind’s unique psychedelics IP TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived […]
TORONTO, Feb. 07, 2022 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its ISO22000 graded Psilocybin production facility has officially received International Organization for Standardization (ISO) 22000:2018 certification, awarded through the British Standards Institute (BSI). […]
Optimi Health Dealer’s License Granted by Health Canada
Optimi Health to become a global leader in all-natural psilocybin production VANCOUVER, BC (February 7, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Optimi Labs […]
Tryp Therapeutics Announces $2,000,000 Financing and Changes in Management, Board of Directors
SAN DIEGO – February 4, 2022 – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, is pleased to announce a non-brokered private placement (the “Placement“) to its co-Founder and Executive Director, William J. Garner, M.D. The Placement consists of […]
Lobe Sciences Ltd. Acquires Securities of Ionic Brands Corp.
Vancouver, British Columbia–(Newsfile Corp. – February 3, 2022) – Lobe Sciences Ltd. (the “Acquiror“) announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 3, 2022, it acquired 47,065,647 common shares in the capital of Ionic Brands Corp. (the “Issuer” and the common shares of the Issuer referred to as the […]
Entheon Biomedical Announces the Approval of DMT Clinical Trial
Vancouver, British Columbia–(Newsfile Corp. – February 03, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the approval by the local Dutch ethics committee of […]
Toronto, Ontario–(Newsfile Corp. – February 3, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that it has entered into a subscription agreement (the “Subscription Agreement“) with respect to a strategic investment (the “Transaction“) with Orthogonal Thinker, Inc. (“Orthogonal […]
Silo Wellness Inc signs distribution deal with Flawless CBD for functional mushroom products
LONDON, Feb. 2, 2022 /PRNewswire/ — Silo Wellness Inc (CNSX: SILO) has signed a distribution deal with UK based Flawless CBD Distribution to distribute the Marley one Brand across the UK. The Marley one brand is a range of functional mushroom products, which are 100% natural and nonpsychedelic, created under the Bob Marley brand. “We have seen […]
Elemental Advisors Launches PSYK ETF Focused on the Medical Psychedelics Industry
SARASOTA, Fla.–(BUSINESS WIRE)–Elemental Advisors Inc. (“Elemental Advisors”) is pleased to announce the launch of PSYK ETF (NYSE: PSYK), a thematic ETF that tracks the performance of the Enhanced Consciousness Index (the “Index”), which is principally comprised of companies involved in the research, development, production and/or use of psychedelics to address medical conditions in legal pharmacological […]
Clearmind Medicine Now Fully Eligible for Settlement through the Depository Trust Company (“DTC”)
TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that the Company’s common shares are now fully eligible for settlement through the Depository […]
The Commercialization of Next Generation Psychedelics for Therapy
Naturally occurring psychedelics, such as psilocybin from mushrooms and DMT from a wide variety of sources, have been shown to act on the nervous system in potentially beneficial ways. Research is happening all over the world. Johns Hopkins has a research center focused on psychedelics, and scientists there have found evidence of psilocybin’s benefit for quitting smokers, […]
A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery […]
Revitalist Executes on Mission to Build a National Network of Ketamine Clinics
Psychedelics have shown tremendous promise in treating depression, anxiety, post-traumatic stress disorder, and a range of other mental health conditions. In particular, assisted psychotherapy combines psychedelic substances with talk therapy to facilitate breakthroughs and help patients that don’t see relief through conventional treatments. While psilocybin, MDMA, and other psychedelic medicines remain in clinical trials, the […]
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel compounds aimed at the serotonin 5-HT2A receptor with other central nervous system (CNS) targets to follow This new platform company is a further step-up in […]
SciSparc Presents New Leadership Lineup
TEL AVIV, Israel, Jan. 27, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), announced that its board of directors (the “Board”) resolved to appoint Mr. Oz Adler as the Chief Executive Officer, Mr. Itschak Shrem as the President of […]
VANCOUVER, British Columbia, Jan. 26, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has signed a consulting agreement with the Universitat de Barcelona (the “University of Barcelona” or the “University”), Faculty of Pharmacy and […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Crop Infrastructure is engaged in the business of investing, constructing, owning and leasing mega-greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations.
Flora is building a connected, design-led collective, of plant-based wellness and lifestyle brands, that delivers the most compelling customer experiences in the world, one community at a time.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
